Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513364 | 0.90 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4477312 | 0.84 | MCHR1 (0.61) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4486672 | 0.81 | MCHR1 (0.59) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4493267 | 0.81 | MCHR1 (0.61) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4475563 | 0.81 | MCHR1 (0.59) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4474578 | 0.80 | MCHR1 (0.60) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4476791 | 0.80 | MCHR1 (0.60) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4469369 | 0.80 | MCHR1 (0.59) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4476794 | 0.79 | MCHR1 (0.57) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4521379 | 0.78 | MCHR1 (0.42) | MCHR1CHRM1HTR2ACYP2D6ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239826-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239826-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, GPR119 | MCHR1 1/4885CHRM1 47/4885HTR2A 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.